CA 15-3 and Related Mucins as Circulating Markers in Breast Cancer

Forbes JF . The control of breast cancer: the role of tamoxifen. Sem Oncol 1997; 24(Suppl 1): 1–19.

McGuire WL . Prognostic factors in primary breast cancer. Cancer Surveys 1986; 5: 527–36.

Duffy MJ . Biochemical markers as prognostic indices in breast cancer. Clin Chem 1990; 36: 188–91.

Duffy MJ . The biochemistry of metastasis. Adv Clin Chem 1996; 32: 135–66.

Ballesta AM Molina R Filella X Jo J Gimenez N . Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumor Biol 1995; 16: 32–41.

Hilkens J Buijs F Hilgers J Hageman P Calafat J Sonnenberg A Monoclonal antibodies against human milk fat globule membranes detecting differentiation antigens of mammary gland and its tumor. Int J Cancer 1984 34: 197–206.

Kufe D Inghirami G Abe M Hayes D Justi-Wheeler H Scholm J . Differential reactivity of a novel monoclonal antibody (DF3) with human malignant versus benign breast tumors. Hybridoma 1984; 3: 223–32.

Gendler SJ Spicer AP . Epithelial mucin genes. Ann Rev Physiol 1995; 57: 607–34.

Price MR Rye PD Petrakou E Murray A Brady K Imai S Summary report on the ISOBM TD-4 workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. J Tumor Biol 1998; 19(Suppl 1): 1–20.

Hilkens J Vos HL Wesseling J Peterse J Storm J Boer M The expression levels of episialin in human cancers are potentially high to potentially interfere with adhesion and promote metastasis. In: Calvo F Crepin M Magdelenat H , eds. Breast Cancer Advances in Biology and Therapeutics. Rontrouge, France: John Libbey Eurotext; 1996:281–8.

Wesseling J van der Valk SW Hilkens J . A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. Mol Biol Cell 1996; 7:565–77.

Jiang WG . E-cadherin and its associated protein catenins, cancer invasion and metastasis. Br J Surgery 1996; 83: 437–46.

Gimmi CD Morrison BW Mainprice BA Gribben JG Boussiotis VA Freeman GJ Breast cancer-associated antigen induces apoptosis of activated human T cells. Nature Med 1996; 2: 1367–70.

Agrawal B Krantz MJ Reddish MA Longenecker BM . Cancer-associated MUC1 mucin inhibits human T-cell proliferation which is reversible by Il-2. Nature Med 1998; 4: 43–9.

Hilkens J Ligtenberg M Vos HL Litinov SV . Cell membrane-associated mucins and their adhesion-modulating properties. Trends Biol Sci 1992; 17: 359–63.

Hayes DF Zurawski VR Kufe D . Comparison of circulating CA 15-3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 1986; 4: 1542–50.

Bon GG Kenemans P Verstraeten R van Kamp GJ Hilgers J . Serum tumor marker immunoassays in gynecologic oncology: establishment of reference values. Am J Obstet Gynecol 1996; 174: 107–14.

Vizcarra E Lluch A Cibrian R Jarque F Alberola V Belloch V Value of CA 15-3 in breast cancer and comparison with CEA and TPA: a study of specificity in disease-free follow-up patients and sensitivity in patients at diagnosis of the first metastasis. Breast Cancer Res Treat 1996; 37: 209–16.

Safi F Kohler I Rottinger E Beger HG . The value of tumor marker CA 15-3 in diagnosis and monitoring breast cancer. Cancer 1991; 68: 574–82.

Duffy MJ Sherry F . CA 15-3, a new marker in breast cancer. Ann Clin Biochem 1988; 25 (Suppl): 53s–4s.

Coveney E Geraghty JG Sherry F McDermott EW O'Higgins NJ Duffy MJ . The clinical value of CEA and CA 15-3 in breast cancer management. Int J Biol Markers 1995; 10: 35–41.

Robertson JFR Pearson D Price MR Selby C Badley RA Pearson J Assessment of four monoclonal antibodies as serum markers in breast cancer. Eur J Cancer 1990; 26: 1127–32.

O'Dwyer PJ Duffy MJ O'Sullivan F McDermott E Losty P O'Higgins N . CEA and CA 15-3 in primary and recurrent breast cancer. World J Surg 1990; 14: 562–6.

Geraghty J Coveney EC Sherry F O'Higgins NJ Duffy MJ . CA 15-3 in patients with locoregional and metastatic breast carcinoma. Cancer 1992; 70: 2831–4.

Colomber R Ruibal A Salvador L . Circulating tumor marker levels in advanced breast cancer correlate with extent of metastatic disease. Cancer 1989; 64: 1674–81.

Duffy MJ Shering SG Sherry F McDermott E O'Higgins N . CA 15-3, a circulating marker with strong prognostic value in breast cancer, new observation. In: Martin SM Halloran SP , eds. Proceedings of the XVI International Congress of Clinical Chemists. London: Association of Clinical Biochemists; 1996: 147 [Abstract No A407].

Shering S Sherry F McDermott E O'Higgins N Duffy MJ . Preoperative CA 15-3 concentrations predict outcome in breast cancer. Cancer 1998; 83: 2521–7.

Horobin JM Browning MCK McFarlane NP Smith G Preece PE Wood RAB Potential use of tumour marker CA 15-3 in the staging and prognosis of patients with breast cancer. J Roy Coll Surg Edinb 1991; 36: 219–21.

Berruti A Tampellini M Torta M Buniva T Gorzegno G Dogliotti L . Prognostic value in predicting overall survival of two mucinous markers: CA 15-3 and CA 125 in breast cancer patients at first relapse of disease. Eur J Cancer 1994; 30A: 2082–4.

Anonymous. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer by the American Society of Clinical Oncology. J Clin Oncol 1996; 14: 2843–77.

Sauer H . Significance of tumor markers during the follow-up of women without symptoms after treatment of primary breast cancer. Anticancer Res 1997; 17: 3059–62.

Nicolini A Anselmi L Michelassi C Carpi A . Prolonged survival by ‘early’ salvage treatment of breast cancer patients: a retrospective 6-year study. Br J Cancer 1997; 76: 1106–11.

Hayes DF Kiang DT Korzun AH Tondini C Wood WC Kufe DW . CA15-3 and CEA spikes during chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol Meeting 1988; 7: 38.

Kiang DT Greenberg LJ Kennedy BJ . Tumor marker kinetics in the monitoring of breast cancer. Cancer 1990; 65: 193–9.

Pilo A Zucchelli GC Cohen R Bizollon C Cappelli G Cianetti A Comparison of immunoassay for tumor markers CA 19-9, CA 15-3 and CA 125: data from an International Quality Assessment Scheme. Tumori 1995; 81: 117–24.

Bon GS von Mensdorff-Pouilly S Kenemans P van Kamp GJ Verstraeten RA Hilgers J Clinical and technical evaluation of ACS BR serum assay of MUC1 gene-derived glycoprotein in breast cancer, and comparison with CA 15-3 assay. Clin Chem 1997; 43: 585–93.

Soletormos G Schioler V Nielsen D Skovsgaard T Dombernowsky P . Interpretation of results for tumor markers on the basis of analytical imprecision and biological variation. Clin Chem 1993; 39: 2077–83.

Dnistrian AM Schwartz MK Greenberg EJ Schwartz DC . BR27.29 as a marker in breast cancer. J Tumor Marker Oncol 1995; 10: 91–7.

Dnistrian AM Schwartz MK Greenberg EJ Smith CA Schwartz DC Maimonis P . Evaluation of a breast cancer antigen assayed on the Ciba Corning ACS:180 automated chemiluminescence system. J Tumour Marker Oncol 1996; 11: 5–10.

Chan DW Beveridge RA Muss H Fritche H Hortobagyi G Theriault R Use of Truquant BR radioimmunoassay for early detection of breast cancer recurrence in patients with stage II and stage III disease. J Clin Oncol 1997; 15: 2322–8.

Bray KR Koda JE Gaur PK . Serum levels and biochemical characteristics of cancer-associated antigen CA-549, a circulating breast cancer marker. Cancer Res 1987; 47: 5853–60.

Sacks NPM Stacker SA Thompson CH Collins JP Russell IS Sullivan JA Comparison of mammary serum antigen (MSA) and CA 15-3 levels in the serum of patients with breast cancer. Br J Cancer 1987; 56: 820–4.

Rasoul-Rockenshaub S Zielinski CC Kubista E Vavra N Pospichil E Staffen A Diagnostic value of mucin-like antigen (MCA) in breast cancer. Eur J Cancer Clin Oncol 1989; 25: 1067–71.

Dhokia B Pectasides D Self C Habib NA Hersham M Wood CB A low pH enzyme linked immunoassay using two monoclonal antibodies for the serological detection and monitoring of breast cancer. Br J Cancer 1986; 54: 885–9.

Dnistrian AM Schwartz MK Greenberg EJ Smith CA Schwartz DC . Evaluation of CA M26, CA M29, CA15-3 and CEA as circulating tumor markers in breast cancer patients. Tumor Biol 1991; 12: 82–90.

Linsley PS Brown JP Magnani JL Horn D . Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res 1988; 48: 2138–48.